cp wire

CP Wire Articles

Intellia Therapeutics Announces WT1 for treating Acute Myeloid Leukemia as Its First Cell Therapy Target

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, and its research collaborator, Ospedale San... read more

Thu, 05/17/18 - 09:35 am
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma

  • Exelixis will receive a milestone payment of $50 million
  • Approval based on Cabometyx vs versus sunitinib in CABOSUN trial
  • Cabometyx was approved for reimbursement in... read more
Thu, 05/17/18 - 09:17 am
Pfizer's LYRICA Meets Primary Endpoint in Phase III Trial in Pediatric Epilepsy

Pfizer Inc. (NYSE: PFE) announced on 5/17/18 positive top-line results of a Phase 3 study examining the use of Lyrica (pregabalin) Oral Solution CV as adjunctive therapy for partial onset seizures... read more

Thu, 05/17/18 - 09:00 am
FDA Accepts Turnstone Biologics' IND for Immunotherapy Targeting HPV Positive Cancers

Turnstone Biologics  announced on 5/16/18 it has received U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug Application (IND) for MG1-HPV for the treatment of... read more

Wed, 05/16/18 - 08:28 am
BioLineRx Receives European Patent Covering BL-8040 with Cytarabine for Acute Myeloid Leukemia

BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX), announced on 5/16/18 that the European Patent Office (EPO) has issued a Decision to Grant a patent claiming the use of BL-8040 with cytarabine, a... read more

Wed, 05/16/18 - 08:25 am

Pages